Insider plans 914-share TSHA stock sale

Taysha Gene Therapies insider Sean McAuliffe has filed to sell additional company stock.

Rhea-AI Filing Summary

Taysha Gene Therapies insider Sean McAuliffe has filed to sell additional company stock. The notice covers 914 shares of common stock, to be sold through Maxim Group LLC on or around February 4, 2026 on Nasdaq, with an aggregate market value of $4,314.08. The filing states that 273,919,373 shares of common stock were outstanding.

The 914 shares come from a restricted stock unit award acquired on February 3, 2026, which vested and was settled in stock as compensation for continued employment. In the past three months, McAuliffe also sold 36,071 shares for $171,337.25 and 10,894 shares for $50,221.34.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the latest Form 144 filing for TSHA disclose?

The filing shows Sean McAuliffe plans to sell 914 shares of Taysha Gene Therapies common stock. The planned sale, via Maxim Group LLC on Nasdaq, has an aggregate market value of $4,314.08 based on the price used in the notice.

Who is selling Taysha Gene Therapies (TSHA) shares in this notice?

The seller is Sean McAuliffe, listed with a care-of address at Taysha Gene Therapies in Dallas, Texas. He is the person for whose account the securities are to be sold under this Rule 144 notice.

How many TSHA shares are covered by this planned Rule 144 sale?

The notice covers 914 shares of Taysha Gene Therapies common stock. These shares are to be sold through broker Maxim Group LLC on or about February 4, 2026, as stated in the filing’s securities information table.

How were the 914 TSHA shares in this filing acquired?

The 914 shares were acquired on February 3, 2026 via a restricted stock unit (RSU) award. The filing explains the RSU vested and was settled in stock, with consideration being McAuliffe’s continued service as an employee of the issuer.

What prior TSHA stock sales by Sean McAuliffe are disclosed?

The document lists two prior sales in the past three months: 36,071 shares of common stock sold on January 23, 2026 for $171,337.25, and 10,894 shares sold on January 26, 2026 for $50,221.34 in gross proceeds.

How many Taysha Gene Therapies shares are outstanding in this filing?

The filing reports that 273,919,373 shares of Taysha Gene Therapies common stock were outstanding. This figure provides context for the relative size of the 914-share sale described in the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 06:41 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001979693
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TAYSHA GENE THERAPIES, INC.
SEC File Number	001-39536
Address of Issuer	3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TEXAS 75247
Phone	214-612-0000
Name of Person for Whose Account the Securities are To Be Sold	Sean McAuliffe
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Affiliate - Chief Business Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Maxim Group LLC 300 Park Avenue, 16th Floor New York NY 10022	914	4314.08	273919373	02/04/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/03/2026	RSU Award	Issuer			914	02/03/2026	Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sean McAuliffe c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX 75247	Common Stock	01/23/2026	36071	171337.25
Sean McAuliffe c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX 75247	Common Stock	01/26/2026	10894	50221.34

144: Remarks and Signature

Remarks	The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
Date of Notice	02/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Sean McAuliffe
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)